Menu
Recruiting NCT06780475

Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma

Observational Merkel Cell Carcinoma of Skin

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Merkel Cell Carcinoma of Skin. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Merkel Cell Carcinoma of Skin

Overview

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

Detailed description

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

Primary outcome measures

  • Anti-MCPyV functionality [Time frame: Day 0 and Day 4]

Eligibility criteria

Inclusion criteria

  • Patients >= 18 years old;
  • Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up;
  • Informed for the study and no-opposed for participation;
  • Affiliated with a social security scheme or in an equivalent situation.

Exclusion criteria

  • Patients ongoing another interventional clinical trial;
  • Patients under guardianship or trusteeship;
  • Pregnancy or breastfeed;
  • Patients refusal.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 1 center
  • Dermato-oncology Department, Ambroise Paré Hospital, APHP — Boulogne-Billancourt

Identifiers

NCT: NCT06780475 · APHP240470 · 2024-A00643-44

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗